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Abstract
Background: Recently, stem cells derived from inflammatory dental pulp tissues (DPSCs-IPs) have demonstrated
regenerative potential, but the real effect remains to be examined. This pilot study attempted to isolate DPSCs-IPs
from two patients and to evaluate the feasibility and the effect of reconstructing periodontal intrabone defects in
each patient.
Methods: DPSCs-IPs were harvested from two patients with periodontal intrabone defects with their approval. After
discussing the biological characteristics of DPSCs-IPs in each patient, DPSCs-IPs were loaded onto the scaffold
material β-tricalcium phosphate and engrafted into the periodontal defect area in the root furcation. After 1,
3, and 9 months, the outcome was evaluated by clinical assessment and radiological study. Furthermore, new
samples were collected and the biological characteristics of DPSCs-IPs were further studied compared with
normal dental pulp stem cells. The primary cell culture success rate, cell viability, cell cycle analysis, and proliferation
index were used to describe the growth state of DPSCs-IPs. In-vitro differentiation ability detection was used to further
discuss the stem cell characteristics of DPSCs-IPs.
Results: As expected, DPSCs-IPs were able to engraft and had an effect of regeneration of new bones to repair
periodontal defects 9 months after surgical reconstruction. Although the success rate of primary cell culture and
growth status was slightly inhibited, DPSCs-IPs expressed comparable levels of stem cell markers as well as retaining
their multidifferentiation ability.
Conclusions: We developed a standard procedure that is potentially safe and technological for clinical periodontal
treatment using human autologous DPSCs-IPs.
Trial registration: According to the editorial policies, the present study is a purely observational study, so trial
registration is not required.
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Background
Periodontitis is a kind of chronic disease prevalent
worldwide, featured by a loss of support tissues around
the teeth, resulting in damage which continues until the
teeth fall out [1]. The final goal of treatment for
periodontitis is to repair the lost periodontal support
tissues, especially the bone. In recent years, the rapid
development of tissue engineering has shown great po-
tential for applications in reconstruction of periodontal-
associated bone defects [2–6]. In particular, the discov-
ery of dental pulp stem cells (DPSCs) and other odonto-
genic stem cells has furnished new prospects for the
repair of periodontal tissue [7, 8]. However, a limitation
for clinical application may be the availability of autolo-
gous DPSCs, particularly for patients who have already
had dental pulp disease and are not willing to sacrifice
normal dental pulp tissues. Moreover, medical wastes
often occur and are discarded when inflammatory pulp
tissues are removed by pulpectomy.
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Recently some studies found that a certain proportion of
ectomesenchymal stem cells were contained within the in-
flammatory dental pulp tissues with retained potential for
tissue regeneration [9–11]. If such tissues could be used as
a kind of available resource in periodontal tissue regener-
ation, this may provide a way of making use of the dis-
carded tissue as well as enabling treatment of periodontal
bone defects without damaging the normal dental pulps.
However, previous studies concentrated only on the
biological characteristics of stem cells isolated from in-
flammatory dental pulp tissues (DPSCs-IPs), without
providing enough information on whether this kind of
stem cell can be used in the clinical process and to de-
termine the effectiveness of regeneration. To address
these issues, the current study utilized DPSCs-IPs in
periodontal treatment with the patient’s consent to pro-
vide primary evidence for future clinical application and
to provide more details of DPSCs-IPs compared with
two kinds of normal DPSCs.
Methods
Patient enrollment
Two female patients diagnosed with combined periodon-
tal–endodontic lesions with pocket depth from 5 to 6 mm
were chosen. Patient No. 1 is 30 years old with 29 teeth;
Patient No. 2, aged 38, has 30 teeth left. Patients were first
informed to consent to the entire treatment. The selected
patients should be in accordance with the following inclu-
sion criteria: age range from 18 to 40 years without sys-
temic disease, no pregnancy or smoking, and no use of
recreational drugs. Patients were excluded if they had
undertaken any initial treatment including subgingival
scaling or root planing within the previous 6 months. Be-
fore this pilot clinical study, approval was obtained from
the Ethics Committee of Stomatological Hospital, College
of Medicine, and Xi’an Jiaotong University (No.2016038).
DPSCs-IPs isolation and cultivation
Inflamed pulps from two patients were extirpated and
placed in D-Hank’s solution. A routine RCT was per-
formed. Inflamed pulps were then quickly placed in cul-
ture medium for cell isolation. Each sample was first
minced and then digested for 1 hour in a solution of
collagenase type I and dispase II (3:4) at 37 °C. Cells
were then incubated in Dulbecco’s modified Eagle
media/Nutrient Mixture F-12 (DMEM/F12 1:1) culture
medium with 10 % fetal bovine serum, 2 mmol/L glu-
tamine, 100 μmol/L L-ascorbic acid-2-phosphate, and an-
tibiotics at 37 °C. The colony formation unit-fibroblasts
(CFU-Fs) were observed 5 days later.
Cell Counting Kit-8 assay
The Cell Counting Kit-8 (CCK-8) assay was utilized to
detect the viability of DPSCs-IPs, 103 cells/ml were
seeded in 96-well plates, and the absorbance at 450 nm
was detected at 1–6 days after seeding.
Osteogenic differentiation
Passage 3 (P3) of DPSCs-IPs was seeded into 12-well
plates at a density of 1 × 105 per well and allowed to at-
tach overnight. Next day, the medium was changed for
osteogenic differentiation induction medium and then
changed every 3 days. Twenty-one days later, cells were
stained with Alizarin red.
Flow cytometry
P3 of DPSCs-IPs were harvested with 0.25 % trypsin, and
were incubated for 30 min at 4 °C with primary antibodies.
The monoclonal primary antibodies (1:500) were mouse
monoclonal anti-human CD44, CD90, CD105, CD117,
CD45, CD34, and CD271. Expression profiles were ana-
lyzed by flow cytometry (Caliber; BD Biosciences) and the
mean fluorescence intensity calculated by flowjo 7.6.3.
Preparation and evaluation of the DPSCs-IPs/β-TCP complex
by scanning electron microscope
Scaffold β-tricalcium phosphate (β-TCP) was placed into
dishes when DPSCs-IPs at P3 were at a confluence of 80 %.
The medium was generally changed every 3 days. Two
weeks later, the complex samples were scraped for scanning
electron microscope analysis. They were first put into 2.5 %
glutaraldehyde for 2 hours, and then washed with PBS and
further fixed with 1 % osmium tetroxide followed by dehy-
dration with ethanol. After displacement, desiccation, and
metal spraying, the samples were ready to observe.
Transplantation of autologous DPSCs-IPs/β-TCP into patients
Patients should undergo initial periodontal therapy be-
fore the DPSCs-IPs/β-TCP treatment. During transplant-
ation surgery, infiltration anesthesia was used first, and
then inflammatory tissues were removed. DPSCs-IPs/β-
TCP was transplanted into the periodontal defect areas
and sutured carefully.
Clinical evaluation
The plaque index (PLI), bleeding index (BI), probing
depth (PD), gingival recession (GR), clinical attachment
level (AL), and tooth mobility were recorded before sur-
gery and post DPSCs-IPs/β-TCP transplantation from 1
to 9 months. All measurements were done with a peri-
odontal probe by blinded examiners.
Sample collection
Third molars, supernumerary teeth, or teeth removed for
orthodontic purposes which were extracted atraumatically
from patients were used as the source of normal pulp tis-
sues. We collected inflammatory pulp tissues from teeth
diagnosed with irreversible pulpitis. Deciduous teeth were
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gathered as the source of stem cells from human exfoli-
ated deciduous teeth (SHED).
Cell cycle analysis
P3 of these cells were trypsined and washed with PBS
twice, and were then fixed in 70 % ethanol at 4 °C over-
night. The next day, they were washed twice with ice-cold
PBS, and stained with PI at a concentration of 50 μg/ml.
The stained cells were finally analyzed by flow cytometry.
In-vitro differentiation and qRT-PCR
P3 of these cells were seeded into six-well plates, and the
medium was changed for induction medium for osteogenic
differentiation, adipogenic differentiation, and chondrogenic
differentiation when the cell confluence reached 90 %.
Twenty-one days later, cells were stained with Alizarin red,
oil-red O, and toluidine blue to visualize the effect.
Expression levels of ALP, OCN, LPL, PPAR-γ2, COL2A1,
and ACAN mRNA were tested after in-vitro differentiation.
Primer sequences are presented in Table 1. The protocols
used for RNA extraction were similar to those reported
previously [12]. Reverse transcription PCR (RT-PCR) was
done using a PCR kit (Takara). The quantification process
was performed using the SYBR green reagent.
Statistical analysis
Student’s t test and ANOVA test was used. P < 0.05 was
considered a significant difference.
Results
Biological characteristics of DPSCs-IPs in Patient No. 1
We objectively evaluated the biological characteristics of
DPSCs-IPs in Patient No. 1. Cell growth was observed at
the very beginning, and in the first 2 days DPSCs-IPs
stayed in the lag phase, while they showed an accelerated
proliferation rate from day 3 to day 6 (Fig. 1a). Twenty-
one days after osteogenic induction, mineralized nodules
were observed by Alizarin red staining (Fig. 1b). Surface
molecule expression of DPSCs-IPs is shown in Fig. 1c, d,
and hematopoietic markers CD34, CD45, and CD117 to-
gether with mesenchymal stem cell markers CD44,
CD90, CD105, and CD271 were used to investigate the
stem cell properties of DPSCs-IPs.
DPSCs-IPs/ β-TCP transplantation in Patient No. 1
Figure 2A clearly shows the protocol of a procedure for
using DPSCs-IPs from patients to treat periodontal bone
defeats. DPSCs-IPs from Patient No. 1 were cultured to
the third passage (Fig. 2Aa). All procedures were done
with the patient’s agreement and her knowledge. To pre-
pare the DPSCs-IPs/β-TCP complex, DPSCs-IPs were
cultured in a 100-mm dish for 3 days, and 40 mg β-TCP
particles were added to the dishes; 2 weeks later, the
complex samples were ready (Fig. 2Ab). We used scan-
ning electron microscopy to detect the DPSCs-IPs/β-
TCP complex (Fig. 2Ac, Ad). After removing infectious
periodontal tissues, the DPSCs-IPs complex was applied
to the periodontal bone defective areas (Fig. 2Ae–g).
After transplanting in-vitro expanded DPSCs-IPs/β-
TCP into the intrabone defects of deep periodontal
pockets in Patient No. 1 following the standard surgical
debridement, the patient was monitored carefully and
followed up at 1, 3, and 9 months. Routine clinical eval-
uations including PD, AL, and GR were examined and
X-ray scans were taken at 1, 3, and 9 months after sur-
gery (Table 2 and Fig. 2B).
Table 1 Primer sequences
Gene Gene bank accession number Primer sequence (5′–3′) Product (base pair)
Reference GAPDH NM_002046.3 Forward: GCACCGTCAAGGCTGAGAAC 138
Reverse: TGGTGAAGACGCCAGTGGA
Osteogenesis ALP NM_000478.4 Forward: CATGCTGAGTGACACAGACAAGAA 141
Reverse: ACAGCAGACTGCGCCTGGTA
OCN NM_199173.4 Forward: ATGAGAGCCCTCAGACTCCTC 297
Reverse: CGGGCCGTAGAAGCGCCGATA
Adipogenesis LPL NM_000237.2 Forward: GTCACGGGCTCAGGAGCATTA 144
Reverse: GCTCCAAGGCTGTATCCCAAGA
PPARγ-2 NM_015869.4 Forward: TGGAATTAGATGACAGCGACTTGG 182
Reverse: CTGGAGCAGCTTGGCAAACA
Chondrogenesis ACAN NM_001135.3 Forward: ACGAAGACGGCTTCCACCAG 134
Reverse: TCGGATGCCATACGTCCTCA
COL2A1 NM_001844.4 Forward: CCAGTTGGGAGTAATGCAAGGA 123
Reverse: ACACCAGGTTCACCAGGTTCA
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DPSCs-IPs/β-TCP transplantation in Patient No. 2
The biological characteristics of DPSCs-IPs in Patient
No. 2 were also evaluated (Fig. 3A–D), and the DPSCs-
IPs/β-TCP complex was prepared as described previ-
ously. X-ray scans were taken at 1, 3, and 9 months
after surgery (Fig. 3E). The proliferation status of
DPSCs-IPs in Patient No. 2 was similar to that in Pa-
tient No. 1. Mineralized nodule formation can be ob-
served 21 days after induction and cells were negative
to hematopoietic markers, but positive to mesenchymal
stem cell markers.
More importantly, DPSCs-IPs also showed an effective
therapeutic effect in Patient No. 2 (Table 3 and Fig. 3E).
Phenotypes of three kinds of DPSCs
As observed previously, DPSCs-IPs have the ability to
restore periodontal bone defeats in two patients; it is
interesting to discuss the biological phenotype of
DPSCs-IPs compared with two other kinds of DPSCs.
We therefore used normal human dental pulp stem cells
(DPSCs-NPs) and deciduous dental pulp stem cells
(SHED) to evaluate the phenotype of DPSCs-IPs (de-
tails of sample collection are presented in Table 4).
The growth state was evaluated by the success rate of
primary culture, the cell proliferation index PI = (G2/
M + S) / (G0/G1 + S + G2/M) × 100 %, and the cell
growth curve. The results showed that in DPSCs-IPs,
compared with the two other kinds of normal cells,
the primary culture success rate decreased (Fig. 4a),
cell growth was slightly restricted (Fig. 4b), and the
cell proliferation index was significantly decreased
(Fig. 4c, d). In summary, although the growth state of
DPSCs-IPs is slightly influenced, these cells can still
be successfully cultured and amplified.
Assessment of the ability of multidirection differentiation
of DPSCs-IPs
Next, we further tested the ability of multidirection dif-
ferentiation of DPSCs-IPs and related gene expression.
DPSCs-IPs were positively stained in osteogenesis, adi-
pogenesis, and chondrogenesis (Fig. 5a). Gene markers
were examined by qRT-PCR at 21 days after in-vitro dif-
ferentiation (Fig. 5b). We found that the ability of osteo-
genic differentiation of DPSCs-IPs slightly decreased,
while the adipogenic and chondrogenic differentiation
ability showed no obvious difference compared with
DPSCs-NPs. These results suggest that although osteo-
genic ability is affected to some extent, DPSCs-IPs still
could be a choice for the replacement of DPSCs-NPs in
clinical practice.
Fig. 1 Biological characteristics of DPSCs-IPs in Patient No. 1. a CCK-8 assay was utilized to detect the viability of DPSCs-IPs. At days 1–2, DPSCs-
IPs stayed in the lag phase, but they showed an elevated proliferation from days 3 to 6. b DPSCs-IPs were cultured with osteogenic differentiation
medium for 21 days. Alizarin red staining showed mineralized nodules (magnification × 40). c Flow cytometry analysis indicated the expression
levels of DPSCs-IPs on hematopoietic markers CD34, CD45, and CD117 as well as the mesenchymal stem cell markers CD44, CD90, CD105, and
CD271. d Mean fluorescence intensity was calculated. (*P < 0.05; ***P < 0.001). Experiments were repeated three times
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Discussion
Previous studies have shown that although they lose
some of the properties of stem cells, DPSCs-IPs retain
the potential for tissue regeneration [9, 10, 13].
In the present study, DPSCs-IPs were transplanted
into the patients’ periodontal bone defects for the first
time and the effective repairing effect was observed.
To date, only a few in-vivo studies in patients have
been reported in oral tissue regeneration instead of only
discussing the biological characteristics of the stem cells.
There are many reasons for this lack of research, but
what is at least certain is that normal dental stem cells
need to be obtained from normal tissues, a process
which itself would be new damage for patients. In this
case, patients often refused the treatment. However,
DPSCs-IPs themselves are derived from the inflamma-
tory dental pulp tissues that are always taken as medical
waste, so it is acceptable for patients to agree with this
kind of treatment.
This study was the first to complete bone regeneration by
autologous transplantation of DPSCs-IPs in patients. We
objectively evaluated the characteristics of DPSCs-IPs in
each patient first. The study found that inflammatory dental
pulp tissues in both patients to a certain extent retain the
properties of DPSCs: they can differentiate into osteogenic
cells, and they express certain surface markers of mesen-
chymal stem cells. The expression levels in CD44 and
CD90 are highly positive, and the levels in CD34 and CD45
Fig. 2 DPSCs-IPs/β-TCP transplantation and therapeutic effect of Patient No. 1. a Procedures for DPSCs-IPs/β-TCP transplantation. (a) Third passage of
DPSCs-IPs from Patient No. 1. (b) Generation of DPSCs-IPs/β-TCP complex. DPSCs-IPs were cultured in 100-mm culture dishes with 40 mg β-TCP
particles. (c, d) Scanning electron microscopy of DPSCs-IPs/β-TCP complex. (e) Lingual view of periodontitis lesion. (f, g) Transplantation of
the DPSCs-IPs/β-TCP complex generated from Patient No. 1 into the periodontal lesion. b Therapeutic effect of DPSCs-IPs/β-TCP in Patient
No. 1. (a) Bone defeats before the operation (red circle in Pre-Op). (b) Therapeutic effect 1 month after the operation (red circle in Post-1 M). (c) Therapeutic
effect 3 months after the transplantation (red circle in Post-3 M). (d) Therapeutic effect 9 months after the operation (red circle in Post-9 M) by X-ray analysis.
DPSCs-IPs dental pulp stem cells isolated from inflammatory dental pulp tissues, β-TCP β-tricalcium phosphate
Table 2 Clinical characteristics of Patient No. 1
Clinical index Before treatment 1 month after treatment 3 months after treatment 9 months after treatment
Dental plaque 3 2 1 1
Sulcus bleeding index 3 2 1 1
Gingival recession (mm) 3 2.5 2.5 2.5
Probing depth (mm) 6 4 3 3
Furcation lesion (degree) III II II II
Mobility (degree) III II I I
Li et al. Stem Cell Research & Therapy  (2016) 7:141 Page 5 of 9
are negative, which is in line with the characterization of
mesenchymal stem cells. But the levels in CD105 and
CD271 are weak, which slightly differs from previous re-
ports [14–16]. However, the underlying reason remains un-
clear. The property of stem cell markers in different species
or organs indeed differs in some cases [9]. Using the
expression levels in CD44, CD90, CD34, and CD45,
however, the stem cell properties of DPSCs-IPs can be
determined. The following discusses the therapeutic
effect of DPSCs-IPs from many aspects. We have
Fig. 3 DPSCs-IPs and the therapeutic effect of Patient No. 2. a Viability of DPSCs-IPs in Patient No. 2. The proliferation status of DPSCs-IPs in Patient No. 2
was similar to that in Patient No. 1. b Mineralized nodule formation can be observed 21 days after osteogenic induction (magnification × 40). c DPSCs-IPs
in Patient No. 2 were negative to hematopoietic markers, but positive to mesenchymal stem cell markers. d Mean fluorescence intensity was also
calculated (*P < 0.05; ***P < 0.001). Experiments were repeated three times. e Therapeutic effect of DPSCs-IPs/β-TCP in Patient No. 2. (a) Bone defeats
before the operation (red circle in Pre-Op). (b) Therapeutic effect 1 month after the operation (red circle in Post-1 M). (c) Therapeutic effect 3 months after
the transplantation (red circle in Post-3 M). (d) Therapeutic effect 9 months after the operation (red circle in Post-9 M) by X-ray analysis
Table 3 Clinical characteristics of Patient No. 2
Clinical index Before treatment 1 month after treatment 3 months after treatment 9 months after treatment
Dental plaque 2 1 1 1
Sulcus bleeding index 3 2 1 1
Gingival recession (mm) 1 1 1 1
Probing depth (mm) 5 4 3 3
Furcation lesion (degree) III II I I
Mobility (degree) II II I I
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provided evidence here that the dental clinical condi-
tion was improved obviously 9 months after transplant-
ation of the DPSCs-IPs/β-TCP complex. As observed in
the clinic, the color of the gum is pink, and its quality
is tough and elastic. Although there is only an incon-
spicuous improvement in GR, the PD was evidently
shallow, the gingival BI decreased from 3 to 1, clinical
hemorrhage disappeared, the root bifurcation lesions
reduced to degree II–I compared with degree III before
treatment, and the treatment effect was obvious from
the current clinical symptoms. Generally speaking, the
DPSCs-IPs/β-TCP autograft dramatically improved the
clinical symptoms of periodontitis. Our results provide
evidence that DPSCs-IPs/β-TCP compounds may have
a certain repair effect on periodontal hard tissue defects
caused by periodontitis and may be a new source for
oral tissue regeneration to provide a potential way of
being used in future clinical applications.
β-TCP has been used in tissue engineering for a long
time, it has excellent bone conductibility, biological activity,
and mechanical performance, and it has certain ability to
repair bone defeats combined with stem cells [17–20]. In
Table 4 Statistical table of dental pulp tissues
Category Total number Success number Success rate Average age Position Primary clone number
(mean ± SD)
Inflammatory dental pulps 25 12 48.00 % 26 Anterior teeth (68.00 %) 33.08 ± 4.963
Molar teeth (32.00 %)
Deciduous dental pulps 30 22 73.33 % 7 Lower anterior teeth 65.41 ± 6.404
Normal dental pulps 34 28 82.35 % 20 Orthodontic teeth (63.33 %) 68.68 ± 6.043
Wisdom teeth (36.67 %)
Fig. 4 Success rate of primary cell culture and growth state of DPSCs-IPs compared with DPSCs-NPs and SHED. Primary cell culture success rate
of three kinds of dental pulp-derived stem cells. a Cell growth curves of three kinds of dental pulp-derived stem cells. b Cell cycle determination
of three kinds of dental pulp-derived stem cells. c Cell proliferation rate of three kinds of dental pulp-derived stem cells. d Cell proliferation index
of three kinds of dental pulp-derived stem cells. *P < 0.05. DPSCs-IPs dental pulp stem cells isolated from inflammatory dental pulp tissues, DPSCs-NPs
dental pulp stem cells from normal dental pulp tissues, SHED stem cells from human exfoliated deciduous teeth
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our study, DPSCs-IPs can be well engrafted into β-TCP,
and no side effect or uncomfortable feelings appeared in
patients after the transplantation. Therefore it is suggested
that β-TCP can be used as a good carrier for tissue repair
in the future.
In the view of safety in the process of transplantation,
no patients showed any systemic disorders related to the
transplantations or adverse reactions during the process,
so the procedures used in this study can benefit DPSCs-
IPs clinical studies in the future.
By further comparing the biological characteristics of
DPSCs-IPs with two kinds of normal DPSCs, we found
that although DPSCs-IPs can be isolated from inflamma-
tory dental tissues, their growth state is inhibited to
some extent due to the inflammatory source, which is in
line with previous reports [21–23]. However, despite the
decreased osteogenic ability compared with normal
DPSCs, the ability to differentiate into osteogenic, adipo-
genic, and chondrogenic cells proved the characteristics of
stem cells and suggests the potential of mesenchymal stem
cells to repair defeats.
Despite these promising results, the flaws of this study
reside mainly in the definite mechanism of DPSCs-IPs-
mediated regeneration and the small number of patients
enrolled. Future studies should concentrate on the
specific mechanism of DPSCs-IPs-mediated tissue re-
generation and include more clinical studies with large
numbers of patients.
Conclusions
In this study, we provide early clinical data as well as ex-
perimental evidence to support the efficacy and safety of
application of autologous DPSCs-IPs related to human
periodontitis treatment of bone defect. We speculate
that DPSCs-IPs can be a suitable cell source and can be
isolated from dental pulps exhibiting inflammation, and
we also speculate that DPSCs-IPs will perform excellent
effects in the treatment of periodontal regeneration. We
hope to design a clinical trial in the future with a large
number of patients to provide further information about
DPSCs-IPs treatment.
Fig. 5 Assessment of multidirection differentiation abilities of DPSCs-IPs. a Induced osteogenesis, adipogenesis, and chondrogenesis were shown
21 days after induction. Scale bars = 100 mm. b Expression levels of ALP, OCN, LPL, PPAR-γ2, COL2A1, and ACAN mRNA of DPSCs-IPs after in-vitro
differentiation. *P < 0.05. DPSCs-IPs dental pulp stem cells isolated from inflammatory dental pulp tissues, DPSCs-NPs dental pulp stem cells from
normal dental pulp tissues
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